Business
Altrova Health Announces Launch of O-Spray Product Line and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) ("Altrova Health" or the "Company") today announced the introduction of O-Spray™, a needle-free sublingual oral spray dosage format designed as an alternative to self-injection, pill, and syringe-based administration. O-Spray is positioned across current and future therapeutic areas including weight management, erectile dysfunction, menopause-related care, and other indications where an..
About this update from Altrova Health Inc.
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) ("Altrova Health" or the "Company") today announced the introduction of O-Spray™, a needle-free sublingual oral spray dosage format designed as an alternative to self-injection, pill, and syringe-based administration. O-Spray is positioned across current and future therapeutic areas including weight management, erectile dysfunction, menopause-related care, and other indications where an oral spray format may be appropriate.","length":556,"tagName":"p"},{"type":"text","content":"Market Context","length":14,"tagName":"p"},{"type":"text","content":"The global GLP-1 receptor agonist market was valued at approximately USD 53.5 billion in 2024 and is projected to reach approximately USD 315 billion by 2035 at a CAGR of 17.5%.1 In Canada, the market generated approximately USD 2.1 billion in 2025 and is projected to reach USD 6.6 billion by 2033 at a CAGR of 14.2%.2 Despite this scale, injectable administration accounted for approximately 83% of global GLP-1 market share by route of administration in 2024, while the oral and alternative delivery segment is projected to be the fastest-growing category going forward.3 O-Spray dosage formats supports prescription-based sublingual alternatives within this context.","length":670,"tagName":"p"},{"type":"text","content":"About O-Spray","length":13,"tagName":"p"},{"type":"text","content":"O-Spray utilizes an airless metered-dose pump that delivers a precise, consistent dose with each actuation. The format requires no needles, preparation, refrigeration, or mixing. Administration involves a quick spray under the tongue, a ten-minute absorption window, and no further steps.","length":288,"tagName":"p"},{"type":"text","content":"Key format features include:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Airless pump technology maintaining formulation stability and consistent dosing","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Compact, discreet design suitable for daily carry; shelf-stable at room temperature","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":162,"olType":false},{"type":"text","content":"The dosage format is a documented consideration in patient engagement. A Canadian study...